Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pancytopenia in tuberous sclerosis.

M Tashiro1, W Hirose, H Hanabusa

  • 1Department of Internal Medicine, Urawa Municipal Hospital, Urawa, Saitama, Japan. mtashiro@mail.cc.tohoku.ac.jp

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|June 2, 2001
PubMed
Summary

Tuberous sclerosis can cause severe anemia and pancytopenia due to bone marrow changes and hypersplenism. Surgical removal of the spleen improved the patient's condition, highlighting a potential treatment avenue.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke.

European journal of neurology·2016
Same author

A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

Switching to low dose of plasma-derived factor VIII/vWF concentrates with Confact(®) -F as salvage immune tolerance induction in haemophilia A patients with inhibitors: five case reports from Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2015

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Tuberous sclerosis (TS) is a rare genetic disorder characterized by the formation of benign tumors in various organs.
  • Hematological abnormalities are not commonly reported in TS, making severe cases like this noteworthy.

Observation:

  • A 46-year-old female patient presented with edema and pancytopenia.
  • Clinical diagnosis of tuberous sclerosis was confirmed with characteristic manifestations including facial adenoma sebaceous, fibromas, subependymal nodules, and renal angiomyolipoma.
  • Radiographic evidence showed significant cortical thickening of long bones and osteosclerotic vertebral findings, indicating reduced hematopoietic space.

Findings:

  • Massive anemia contributed to hypercardiac function and edema.
  • Pancytopenia was attributed to a combination of hypersplenism and reduced hematopoietic space.

Related Experiment Videos

  • Splenectomy led to improvement in pancytopenia, though the direct link between intrasplenic hemangiomas and hypersplenism remained unclear.

    • Implications:

    • This case underscores the potential for severe and diverse systemic complications in tuberous sclerosis.
    • It highlights the critical role of hematological evaluation in TS patients presenting with cytopenias.
    • The findings suggest that managing hypersplenism and addressing bone marrow involvement may be crucial for improving hematological parameters in TS.